RemedyBio is now supported through funding from the Irish Research Council to investigate patient stratification and therapeutic development using mass scale single cell analysis, in partnership with Dublin City University. This adds to our existing programme, also supported by IRC, in patient-guided immunological studies for the development of cancer therapies.
Related Posts
Dan Crowley, CEO of RemedyBio, to Speak at the 7th Annual Allogeneic Cell Therapies Summit 2025 in Boston
karlobrienMarch 31, 2025
RemedyBio CEO to Chair Single Cell Technologies Session at BiotechX
karlobrienSeptember 19, 2024